Diabetes

The prevalence of insulin pump use for Black beneficiaries increased from 3.9% to 4.6% between 2017 and 2019.

The addition of a pharmacist to a diabetes management team increases therapy optimization and medication access while enhancing patient care.

Prescription fills decreased most significantly in a subgroup of adults.

Lockdown orders impacted how diabetes care was provided for new onset T1D.

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults with chronic kidney disease (CKD) associated with type 2 diabetes.

Learn more about controlling pediatric type 1 diabetes through pharmacist recommendations and families who address common misconceptions.

The CDC estimates that 83 million Americans have prediabetes and that 84% of them don’t know it and community pharmacy can play a major role in preventing diabetes.

Although the authors say their findings shed light on possible disruptions to insulin supply during COVID-19, they note they could not adjust for those with diabetes who died.

Five medications are currently approved by the FDA for chronic weight management.

The FDA has granted approval of the first interchangeable biosimilar insulin product, insulin glargine-yfgn (Semglee; Mylan Pharmaceuticals), for diabetes.

The FDA has approved the AstraZeneca once-weekly injectable therapy for use in children aged 10 to 17 years.

At the virtual Scientific Sessions for the American Diabetes Association, Jennifer Sherr, MD, discussed the findings of a study of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes.

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.

At the virtual Scientific Sessions for the American Diabetes Association, a study shows that metformin can improve adolescent type 1 diabetes.

A study presented at the American Diabetes Association Virtual 81st Scientific Sessions compared flash glucose monitoring with self-monitoring of blood glucose in patients with diabetes and moderate-to-advanced chronic kidney disease.

A study presented at the American Diabetes Association Virtual 81st Scientific Sessions evaluated metformin prescribing for patients with type 2 diabetes and chronic kidney disease.

A poster presented at the American Diabetes Association Virtual 81st Scientific Sessions highlighted the effect of a physician-pharmacist collaborative management team in diabetes preventative care services.

A study presented during a poster session at the American Diabetes Association Virtual 81st Scientific Sessions evaluated performance, safety, and satisfaction of an extended-wear insulin infusion set in patients with type 1 diabetes.

A session from the 2021 PQA Annual Meeting highlighted the benefits of virtual outreach in advancing patient care amid the COVID-19 pandemic and beyond.

Individuals with prediabetes may be at increased risk of suffering an adverse cardiovascular event.

A session at the 2021 Pharmacy Quality Alliance Meeting explored the results of Walgreens’ recent initiatives focused on addressing social determinants of health.

Technology and mobile health apps can be valuable tools in diabetes management.

Dapagliflozin (Farxiga; AstraZeneca) is the first SGLT2 inhibitor approved for the treatment of chronic kidney disease regardless of diabetes status.

A session held during the American Pharmacists Association 2021 Annual Meeting and Exposition provided an update on diabetes practice changes and new treatments.

Dasiglucagon (Zegalogue; Zealand Pharma) showed clear clinical benefit in median time to blood glucose recovery, according to 3 clinical trials.

Once-weekly semaglutide 2.4 mg resulted in sustained reductions in weight for those who are overweight or obese, the investigators reported.

Insulin resistance and type 2 diabetes were major contributors to premature coronary heart disease, according to the study results.